drugset / Trial / NCT07055880

Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)

NCT07055880

Phase 2 Not yet recruiting 120 enrolled Sinovac Biotech Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.

Timeline

Start
2025-07-28
Primary completion
2026-01-15
Completion
2026-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabies Vaccine (Serum-free Vero Cell) Vaccine Intramuscular
Comparator Rabies vaccine Vaccine Intramuscular

Indications